nach oben

Erschienen in:

30.09.2023 | ORIGINAL ARTICLE

Trends in the disease burden of musculoskeletal disorders in Mexico from 1990–2019

verfasst von: Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Pamela Munguía-Realpozo, Juan Carlos Solis-Poblano, Ángel David Osorio-Peña, Diana Zárate-Arellano, Socorro Méndez-Martínez, Mario García-Carrasco

Erschienen in: Clinical Rheumatology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to describe the disease burden and trends of musculoskeletal (MSK) disorders in Mexico from 1990 to 2019.

Method

A cross-sectional study using systematic analysis from the Global Burden of Disease Study 2019 (GBD study 2019) was performed to analyze data on MSK disorders and estimate crude and age-standardized rates per 100,000 population concerning disease prevalence, incidence, mortality, disability-adjusted life-years (DALY), and years lived with disability (YLD). The average annual percentage change (AAPC) was calculated using the joinpoint regression.

Results

In 2019, there were 4.8 million (95% UI 4.3, 5.4) new cases and 3,312 (95% UI 2201, 4,790) deaths attributable to MSK disorders. In 2019, MSK disorders ranked first, increasing from 1990 (second rank) for the YLD in Mexico. Subnational variations were identified, with the state of Oaxaca having the highest age-standardized incidence rate (ASIR) per 100,000 population in 2019. Joinpoint analysis revealed a significant increase in prevalence in Mexico from 1990 to 2019 (AAPC: 0.14%; 95%CI 0.09–0.19), incidence (AAPC: 0.05%; 95%CI 0.03–0.07), DALY (AAPC: 0.13%; 95%CI 0.04–0.22), and YLD (AAPC: 0.13%; 95%CI 0.02–0.24). Among the risk factors, occupational ergonomic factors and high body mass index (BMI) had the largest influence on MSK disorders.

Conclusions

In Mexico, we observed an increase the national burden of MSK disorders from 1990 to 2019. Specific determinants, such as occupational ergonomic factors and high BMI, contribute to the MSK disorder burden. The burden of MSK disorders requires an improved and prompt assessment to plan valuable diagnostic and management approaches.

Key Points

• In Mexico, the burden of musculoskeletal (MSK) disorders increased from 1990 to 2019.

• Specific risk factors, such as occupational ergonomic factors and high body mass index, contribute to the MSK disorder burden.

Nur mit Berechtigung zugänglich

GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 396:1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9CrossRef

Clark P, Denova-Gutiérrez E, Razo C et al (2018) The burden of musculoskeletal disorders in Mexico at national and state level, 1990–2016: estimates from the global burden of disease study 2016. Osteoporos Int 29:2745–2760. https://doi.org/10.1007/s00198-018-4698-zCrossRefPubMed

Safiri S, Kolahi AA, Hoy D et al (2019) Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis 78:1463–1471. https://doi.org/10.1136/annrheumdis-2019-215920CrossRefPubMed

Safiri S, Kolahi A-A, Smith E et al (2020) Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis 79:819–828. https://doi.org/10.1136/annrheumdis-2019-216515CrossRefPubMed

Chen S, Chen M, Wu X et al (2022) Global, regional and national burden of low back pain 1990–2019: a systematic analysis of the global burden of disease study 2019. J Orthop Transl 32:49–58. https://doi.org/10.1016/j.jot.2021.07.005CrossRef

de Melo Castro Deligne L, Rocha MCB, Malta D et al (2021) The burden of neck pain in Brazil: estimates from the global burden of disease study 2019. BMC Musculoskelet Disord 22:811. https://doi.org/10.1186/s12891-021-04675-xCrossRefPubMedPubMedCentral

Safiri S, Kolahi A-A, Cross M et al (2020) Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990–2017: a systematic analysis of the global burden of disease study 2017. Arthritis Rheumatol 72:1916–1927. https://doi.org/10.1002/art.41404CrossRefPubMed

Safiri S, Kolahi AA, Cross M et al (2021) Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the global burden of disease study 2017. Rheumatol 60:855–865. https://doi.org/10.1093/rheumatology/keaa315CrossRef

GBD (2016) (2017) Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259

10.

Lewis R, Gómez Álvarez CB, Rayman M et al (2019) Strategies for optimising musculoskeletal health in the 21(st) century. BMC Musculoskelet Disord 20:164. https://doi.org/10.1186/s12891-019-2510-7CrossRefPubMedPubMedCentral

11.

Woolf AD, Akesson K (2001) Understanding the burden of musculoskeletal conditions. The burden is huge and not reflected in national health priorities. BMJ 322:1079–1080CrossRefPubMedPubMedCentral

12.

Liu S, Wang B, Fan S et al (2022) Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study. BMJ Open 12:e062183. https://doi.org/10.1136/bmjopen-2022-062183CrossRefPubMedPubMedCentral

13.

Jin Z, Wang D, Zhang H et al (2020) Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis 79:1014–1022. https://doi.org/10.1136/annrheumdis-2020-217050CrossRefPubMed

14.

Zamora-Macorra M, Reding-Bernal A, Martínez Alcántara S, de Los Ángeles Garrido González M (2019) Musculoskeletal disorders and occupational demands in nurses at a tertiary care hospital in Mexico City. J Nurs Manag 27(1084):1090. https://doi.org/10.1111/jonm.12776CrossRef

15.

Franco Chavez SA, Salazar Páramo M, Peña Ortiz MO, Aguilera Velasco M de los M (2017) Musculoskeletal diseases caused by ergonomic agents on workers affiliated to the Mexican Institute of Social Security, Mexico. Rev Int Humanidades Médicas 6:1–5. https://doi.org/10.37467/gka-revmedica.v6.1466CrossRef

16.

Global Burden of Disease Study 2019 (GBD 2019) Socio-Demographic Index (SDI) 1950–2019. https://ghdx.healthdata.org/record/ihme-data/gbd-2019-socio-demographic-index-sdi-1950-2019. Accessed 10 Sep 2022

17.

Peláez-Ballestas I, Sanin LH, Moreno-Montoya J et al (2011) Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol 86:3–8. https://doi.org/10.3899/jrheum.100951CrossRef

18.

Del Río ND, González-Chávez SA, Quiñonez-Flores CM et al (2016) Prevalence of rheumatic diseases in Chihuahua, Mexico: a COPCORD survey. J Clin Rheumatol 22:188–193. https://doi.org/10.1097/RHU.0000000000000380CrossRef

19.

Julián-Santiago F, García-García C, García-Olivera I et al (2016) Epidemiology of rheumatic diseases in Mixtec and Chontal indigenous communities in Mexico: a cross-sectional community-based study. Clin Rheumatol 35(Suppl 1):35–42. https://doi.org/10.1007/s10067-015-3148-yCrossRefPubMed

20.

Alvarez-Nemegyei J, Peláez-Ballestas I, Sanin LH et al (2011) Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. J Rheumatol 86:21–25. https://doi.org/10.3899/jrheum.100954CrossRef

21.

GBD (2017) (2018) DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1859–1922. https://doi.org/10.1016/S0140-6736(18)32335-3CrossRef

22.

Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351. https://doi.org/10.1002/(sici)1097-0258(20000215)19:3%3c335::aid-sim336%3e3.0.co;2-zCrossRefPubMed

23.

Ramírez Sepúlveda JI, Bolin K, Mofors J et al (2019) Sex differences in clinical presentation of systemic lupus erythematosus. Biol Sex Differ 10:60. https://doi.org/10.1186/s13293-019-0274-2CrossRefPubMedPubMedCentral

24.

Urowitz MB, Ohsfeldt RL, Wielage RC et al (2020) Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. Lupus Sci Med 7:e000412. https://doi.org/10.1136/lupus-2020-000412

25.

Urowitz MB, Aranow C, Asukai Y et al (2022) Impact of belimumab on organ damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 74:1822–1828. https://doi.org/10.1002/acr.24901CrossRefPubMed

26.

Goeppel C, Frenz P, Grabenhenrich L et al (2016) Assessment of universal health coverage for adults aged 50 years or older with chronic illness in six middle-income countries. Bull World Health Organ 94:276–285. https://doi.org/10.2471/BLT.15.163832CrossRefPubMedPubMedCentral

27.

Álvarez-Hernández E, Peláez-Ballestas I, Boonen A et al (2012) Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. Reumatol Clin 8:168–173. https://doi.org/10.1016/j.reuma.2012.05.002CrossRefPubMed

28.

Mendoza-Pinto C, Etchegaray-Morales I, Garcia-Carrasco M et al (2022) Twenty-year trends in all-cause mortality of patients with systemic lupus erythematosus in Mexico: results from a nationwide health registry. Lupus 31:382–391. https://doi.org/10.1177/09612033221078228CrossRefPubMed

29.

García-Carrasco M, Mendoza-Pinto C, Etchegaray-Morales I et al (2022) Temporal trends in mortality in patients with systemic sclerosis in public hospitals across Mexico from 1998–2017. Arch Med Res 53:610–616. https://doi.org/10.1016/j.arcmed.2022.07.005CrossRefPubMed

30.

Scherlinger M, Mertz P, Sagez F et al (2020) Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev 19:102531. https://doi.org/10.1016/j.autrev.2020.102531CrossRefPubMed

31.

Dziedzic KS, French S, Davis AM et al (2016) Implementation of musculoskeletal models of care in primary care settings: theory, practice, evaluation and outcomes for musculoskeletal health in high-income economies. Best Pr Res Clin Rheumatol 30:375–397. https://doi.org/10.1016/j.berh.2016.08.004CrossRef

32.

Callahan LF, Cleveland RJ, Allen KD, Golightly Y (2021) Racial/Ethnic, socioeconomic, and geographic disparities in the epidemiology of knee and hip osteoarthritis. Rheum Dis Clin North Am 47:1–20. https://doi.org/10.1016/j.rdc.2020.09.001CrossRefPubMed

33.

Consolaro A, Giancane G, Alongi A et al (2019) Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health 3:255–263. https://doi.org/10.1016/S2352-4642(19)30027-6CrossRefPubMed

34.

Gómez-Dantés H, Lamadrid-Figueroa H, Cahuana-Hurtado L et al (2016) The burden of cancer in Mexico, 1990–2013. Salud Publica Mex 58:118–131. https://doi.org/10.21149/spm.v58i2.7780CrossRefPubMed

35.

Diaz D, Vazquez-Polanco AM, Argueta-Donohue J et al (2018) Incidence of intestinal infectious diseases due to protozoa and bacteria in Mexico: analysis of National Surveillance Records from 2003 to 2012. Biomed Res Int 2018:2893012. https://doi.org/10.1155/2018/2893012CrossRefPubMedPubMedCentral

36.

Safiri S, Kolahi AA, Cross M et al (2021) Prevalence, deaths, and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories 1990–2017. Arthritis Rheumatol 73:702–714. https://doi.org/10.1002/art.41571CrossRefPubMed

Titel: Trends in the disease burden of musculoskeletal disorders in Mexico from 1990–2019
verfasst von: Claudia Mendoza-Pinto
Ivet Etchegaray-Morales
Pamela Munguía-Realpozo
Juan Carlos Solis-Poblano
Ángel David Osorio-Peña
Diana Zárate-Arellano
Socorro Méndez-Martínez
Mario García-Carrasco
Publikationsdatum: 30.09.2023
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 1/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06775-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever

Elevated plasma levels of specific antiplatelet glycoprotein autoantibodies in patients with primary Sjögren syndrome with thrombocytopenia

Renal artery involvement is associated with increased morbidity but not mortality in Takayasu arteritis: a matched cohort study of 215 patients

Decreased expression of TIGIT on CD14 + monocytes correlates with clinical features and laboratory parameters of patients with primary Sjögren’s syndrome

Hyposalivation and periodontal disease as oral non-articular characteristics in rheumatoid arthritis